Capital Research & Management Co has recently announced that it has increased stake in Takeda Pharmaceutical Co ADR (NYSE:TAK) by 0.05%. After grabbing 13.79 million shares, the institutional investor is now in possession of 6518.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.44% having worth around $195.19 million. Moreover, Parametric Portfolio Associates L increased its share by 0.14 million to have a control over 4.41 million shares. And Millennium Management LLC raised its holdings to 0.68 million shares by acquiring 3.76 million shares or 0.12% of the stake.
Takeda Pharmaceutical Co ADR (TAK) concluded trading on 12/21/23 at a closing price of $13.97, with 2.03 million shares of worth about $28.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.25% during that period and on Thursday the price saw a gain of about 2.05%. Currently the company’s common shares owned by public are about 3.14B shares, out of which, 3.14B shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 17 analysts are covering the TAK stock and their offered price forecasts bring an average price target of $4683.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $5800.00 and could fall to a lowest price of $4100.00. The stock’s current price level is 12.03% above of average price target set by the analysts, while a rise to estimated low would result in gain of 99.66% for the stock. However, touching the estimated high of $5800.00 would mean a gain of 99.76% for the stock.
American Mutual Fund, VanEck Pharmaceutical ETF, and Pacer Fds. Tr. – Global Cash Cows are the top 3 mutual funds which are holding stakes in Takeda Pharmaceutical Co ADR American Mutual Fund is currently holding 13.65 million shares of worth totaling $193.19 million. The company recently came selling 28415.0 shares which brought its stake up to 0.43% of the company’s outstanding shares. Pacer Fds. Tr. – Global Cash Cows, after buying 0.94 million shares, have now control over 0.03% of the stake in the company. It holds 0.0 shares of worth $13.37 million.
Takeda Pharmaceutical Co ADR (NYSE: TAK) started trading at $13.97, above $0.28 from concluding price of the previous day. However, the stock later moved at a day high price of 14.01, or with a gain of 2.05%. Stock saw a price change of -0.57% in past 5 days and over the past one month there was a price change of -0.36%. Year-to-date (YTD), TAK shares are showing a performance of -10.45% which decreased to -8.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.19 but also hit the highest price of $17.15 during that period. The average intraday trading volume for Takeda Pharmaceutical Co ADR shares is 1.94 million. The stock is currently trading -0.20% below its 20-day simple moving average (SMA20), while that difference is down -0.74% for SMA50 and it goes to -9.66% lower than SMA200.
Capital Research & Management Co acquired 13.79 million shares of Takeda Pharmaceutical Co ADR having value of about $195.19 million. Data submitted at the U.S SEC by Capital Research & Management Co revealed that the firm now holds 6518.0 shares in the company valued at close to $91056.46, or have control over 0.05% stake in the company. Takeda Pharmaceutical Co ADR (NYSE: TAK) currently have 3.14B outstanding shares and institutions hold larger chunk of about 2.56% of that. Holding of mutual funds in the company is about 0.57% while other institutional holders and individual stake holders have control over 1.96% and — of the stake respectively.
The stock has a current market capitalization of $43.84B and its 3Y-monthly beta is at 0.64. PE ratio of stock for trailing 12 months is 31.56, while it has posted earnings per share of $0.44 in the same period. Its PEG reads 1578.17 and has Quick Ratio of 0.55 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TAK, volatility over the week remained 1.34% while standing at 0.98% over the month.
Analysts are in expectations that Takeda Pharmaceutical Co ADR (TAK) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -56.53% while it is estimated to increase by 59.47% in next year. EPS is likely to grow at an annualized rate of 0.02% for next 5-years, compared to annual growth of -6.94% made by the stock over the past 5-years.
Analysts at 17 brokerage firms have issued recommendations for the Takeda Pharmaceutical Co ADR (TAK)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.06. Out of those 17 Wall Street analysts, 7 recommended a “Buy” rating, while 8 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 16, 2023 offering a Buy rating for the stock and assigned a target price of $20 to it.
